Physician profile
Jaime Betancourt
NPI 1801098884
$286,332.59
in general payments reported to CMS, 2019-2025
11 companies · $54K in 2025
The $54K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37K · 2020: $26K · 2021: $35K · 2022: $50K · 2023: $58K · 2024: $26K · 2025: $54K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $63K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47K · Education: $12K · Travel and Lodging: $12K · Food and Beverage: $3,228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $63,144.37 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $47,150.00 |
| Education | $12,089.99 |
| Travel and Lodging | $11,940.76 |
| Food and Beverage | $3,227.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $136,369.92 | 2019-2025 | Ofev, Jascayd |
| Vapotherm INC | $130,542.64 | 2019-2025 | Vapotherm |
| Intuitive Surgical, INC. | $13,881.17 | 2022-2025 | Da Vinci Surgical System, Ion |
| Genzyme Corporation | $4,409.67 | 2025 | |
| Pulmonx Corporation | $489.25 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $214.99 | 2022-2025 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals Lp | $138.10 | 2021-2024 | Tagrisso |
| Bayer Healthcare Pharmaceuticals INC. | $122.27 | 2019 | |
| Pfizer INC. | $84.08 | 2019 | |
| Stemline Therapeutics INC. | $62.27 | 2025 | Orserdu |
| Alexion Pharmaceuticals, INC. | $18.23 | 2025 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Betancourt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.